ESTRO 2024 - Abstract Book

S1536

Clinical - Lower GI

ESTRO 2024

addition to standardised questionnaires, the application also allows the monitoring of symptoms of interest selected by the clinician and/or patient.

Results:

For AI algorithms, data are continuously recorded by the IoT and may provide a solid basis for identifying reliable predictors of toxicity and aggravation risk. Toxicity is assessed according to the NCI-PRO-CTCAE™ ITEMS-ITALIAN Version 4.0.The artificial intelligence and machine learning models used in the project include classical statistical models up to Deep Learning techniques, both with regression and classification functions. So far, 18 patients have been enrolled (1 with pancreatic cancer, 7 with anal cancer and 10 with prostate cancer). No significant warnings have been detected in basic vital parameters, sleep quality, nutrition and physical activity during the whole treatment nor deterioration in QoL has been reported.

Final scores from EORTC questionnaires are being collected and pending to be validated.

Conclusion:

This model based on predictions provided by AI can be useful for the assessment of patients with an indication for radiotherapy to prevent possible toxicities and for the early identification of high-risk patients.

Keywords: Quality of life, anal cancer

2116

Digital Poster

Outcomes of EBRT and brachytherapy in anal cancer: retrospective analysis between 2016 and 2021

Irina Guimarães 1 , Beatriz Pires 1 , David Rothwell 1 , Joana Costa Sousa 1 , Ricardo Magalhães 1 , Mónica Henriques 1 , Paula Alves 1,2 1 Instituto Português de Oncologia de Coimbra (IPOCFG-EPE), Radiotherapy, Coimbra, Portugal. 2 Universidade de Coimbra, Faculdade de Medicina, Coimbra, Portugal

Purpose/Objective:

Anal carcinoma is a rare entity, frequently associated with the human papilloma virus (HPV). Definitive chemoradiotherapy remains a standard because it provides increased rates of locoregional control of the disease and functional organ preservation. Our purpose is to evaluate the clinical outcomes of external beam radiotherapy and brachytherapy in localized and locally advanced anal cancer treated at a tertiary center.

Material/Methods:

We reviewed 21 cases of anal cancer treated during the period from January 2016 to December 2021. Inclusion criteria were stages I to III (by AJCC 8th edition) that underwent definitive chemoradiotherapy or intensive radiotherapy with or without high dose-rate brachytherapy(HDR-BT), or treated with HDR-BT alone after excision.